Personalized approach to pharmacotherapy of overactive bladder
Urology reports (St. - Petersburg) · 17.11.2023 · 13 (3) · 267-282
DOI: 10.17816/uroved569404 ↗Kurz gefasst
Fachartikel in der Zeitschrift Urology reports (St. - Petersburg), online erschienen am 17.11.2023. Verfasst von Igor V. Kuzmin. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 92 Literaturangaben.
Abstract (Originalsprache)
The article provides an overview of modern approaches to pharmacotherapy of overactive bladder. It has been shown that the choice of drug therapy for overactive bladder should be made taking into account the pathophysiological mechanisms of the development of the disease, the characteristics of its clinical course, as well as the potential risks of developing side effects of treatment. A pathogenetic rationale for the choice of treatment tactics for different categories of patients is presented, including those with a hypersensitive bladder, bladder outlet obstruction, neurological and geriatric patients. The pharmacological properties of the β3-adrenergic receptor agonist mirabegron are described, which provide high efficacy and a favorable safety profile in the treatment of patients with overactive bladder. The practical issues of prescribing mirabegron in various clinical situations are considered.
Zitieren
APA
Kuzmin, I. V. (2023). Personalized approach to pharmacotherapy of overactive bladder. Urology reports (St. - Petersburg), 13(3), 267-282. https://doi.org/10.17816/uroved569404
Vancouver
Kuzmin IV. Personalized approach to pharmacotherapy of overactive bladder. Urology reports (St. - Petersburg). 2023;13(3):267-282. doi:10.17816/uroved569404
BibTeX
@article{Kuzmin2023,
author = {Kuzmin, Igor V.},
title = {Personalized approach to pharmacotherapy of overactive bladder},
journal = {Urology reports (St. - Petersburg)},
year = {2023},
volume = {13},
number = {3},
pages = {267--282},
doi = {10.17816/uroved569404}
}
EUVIMED